MeiraGTx Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx or view top-rated stocks.

Wall Street analysts have given MeiraGTx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MeiraGTx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

MeiraGTx is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for MeiraGTx.

MeiraGTx Holdings plc (NASDAQ:MGTX) issued its quarterly earnings data on Thursday, March, 11th. The company reported ($0.25) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.05. The business earned $3.79 million during the quarter, compared to analyst estimates of $3.20 million. MeiraGTx had a negative trailing twelve-month return on equity of 29.14% and a negative net margin of 283.20%.
View MeiraGTx's earnings history.

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MGTX shares have increased by 1.5% and is now trading at $14.31.
View which stocks have been most impacted by COVID-19.

4 brokers have issued 12-month target prices for MeiraGTx's stock. Their forecasts range from $20.00 to $45.00. On average, they expect MeiraGTx's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price.
View analysts' price targets for MeiraGTx or view top-rated stocks among Wall Street analysts.

Some companies that are related to MeiraGTx include Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), NantKwest (NK), Rubius Therapeutics (RUBY), Kymera Therapeutics (KYMR), Krystal Biotech (KRYS), Sangamo Therapeutics (SGMO), Immunovant (IMVT), REGENXBIO (RGNX), Translate Bio (TBIO), AlloVir (ALVR), Alector (ALEC), Replimune Group (REPL) and C4 Therapeutics (CCCC).
View all of MGTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGTX stock can currently be purchased for approximately $14.31.

MeiraGTx has a market capitalization of $633.42 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

MeiraGTx employs 219 workers across the globe.

The official website for MeiraGTx is www.meiragtx.com.

MeiraGTx is headquartered at 450 East 29thStreet 14thFloor, NEW YORK NY, 10016.

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]